Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Mesoblast (MSB AU): Ryoncil Starts on a High Note- A Step Toward Profitable Growth

Mesoblast (MSB AU): Secures New Fund Amid Ongoing Commercialization of Ryoncil and Pipeline Progress

Mesoblast (MSB AU): Strong Q1 Result; Ryoncil Commercialization and Pipeline Progress Hold Key

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/mesoblast-ltd" target="_blank" data-smartkarma-citation="entities:769:1" rel="noopener">Mesoblast Ltd (MSB AU)</a> achieved its target of at least 300 patients treated in Phase 3 trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease.</li>
<li>Mesoblast’s sole commercialized product, Ryoncil recorded revenue of $36M for Q4FY26, up from $30M in Q3FY26. For FY26, the drug recorded revenue of $115M, against guidance of $110–120M.</li>
<li>Mesoblast seems to be well-positioned for long-term growth. The company is expected to become profitable in FY27. Next catalyst is FY27 Ryoncil revenue guidance to be announced in late August.</li>
</ul>



Mesoblast Ltd (MSB AU) achieved its target of at least 300 patients treated in Phase 3 trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease.
Mesoblast’s sole commercialized product, Ryoncil recorded revenue of $36M for Q4FY26, up from $30M in Q3FY26. For FY26, the drug recorded revenue of $115M, against guidance of $110–120M.
Mesoblast seems to be well-positioned for long-term growth. The company is expected to become profitable in FY27. Next catalyst is FY27 Ryoncil revenue guidance to be announced in late August.


Mesoblast (MSB AU): Decoding the Recent Powerful Rally; It’s Time to Focus on Long-Term Growth